Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Short Interest Up 95.9% in June

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw a significant increase in short interest in June. As of June 15th, there was short interest totaling 65,485 shares, an increase of 95.9% from the May 31st total of 33,421 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average trading volume of 64,658 shares, the days-to-cover ratio is currently 1.0 days.

Wall Street Analysts Forecast Growth

NBTX has been the subject of a number of research reports. Leerink Partners increased their price objective on Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a report on Thursday, June 4th. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Finally, Guggenheim raised their target price on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.33.

Nanobiotix Stock Performance

Shares of NBTX stock opened at $38.40 on Friday. Nanobiotix has a 12-month low of $4.79 and a 12-month high of $57.14. The firm’s 50 day moving average is $38.97 and its 200 day moving average is $30.95.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $3.42 million during the quarter. On average, analysts predict that Nanobiotix will post 0.19 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC bought a new position in Nanobiotix in the fourth quarter worth approximately $390,000. Royal Bank of Canada lifted its position in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in Nanobiotix during the fourth quarter valued at about $220,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.